Related Experiment Video
Updated: May 18, 2026
08:48
An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation
Published on: June 30, 2015
PI3K pathway inhibitors: better not left alone.
Ben Markman1, Jessica J Tao, Maurizio Scaltriti
1Monash Medical Centre, Southern Health, Melbourne, Australia 3165.
Current Pharmaceutical Design
|September 15, 2012
Summary
The PI3K/Akt/mTOR pathway is crucial in cancer, but inhibitors show limited efficacy due to complex signaling. Combination therapies targeting this pathway show promise in new clinical trials.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- The Phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian Target of Rapamycin (mTOR) signaling pathway regulates vital physiologic processes.
- Constitutive activation of this pathway, often due to PI3K mutations or PTEN loss, is prevalent in human cancers.
- This pathway is a significant target for developing novel cancer therapeutics.
Purpose of the Study:
- To review PI3K/Akt/mTOR pathway inhibitors evaluated in early-phase clinical studies.
- To discuss the rationale and application of novel therapeutic combination strategies targeting this pathway.
Main Methods:
- Review of agents targeting key nodes within the PI3K pathway.
- Analysis of preclinical studies and emerging clinical trials on combination therapies.
- Evaluation of early-phase clinical studies in human cancer subjects.
Main Results:
- Numerous PI3K pathway inhibitors are in development, but their efficacy has been limited.
- Feedback loops and cross-talk within and between signaling pathways may explain suboptimal responses.
- Therapeutic combinations targeting the PI3K pathway demonstrate encouraging preclinical and early clinical results.
Conclusions:
- Despite challenges, the PI3K/Akt/mTOR pathway remains a critical focus for cancer therapy.
- Combination strategies are gaining momentum, offering a promising approach to overcome resistance and improve treatment outcomes.
- Further investigation into novel drug combinations is warranted to enhance efficacy in cancer treatment.
Related Concept Videos
01:22PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...
01:19Interactions Between Signaling Pathways
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
01:20The JAK-STAT Signaling Pathway
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
01:42Phosphoinositides and PIPs
Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...